Bayer AG has patented new potassium channel Kir3.4 (GIRK4; KCNJ5) and/or Kir3.1/3.4 (GIRK1/4; KCNJ3/5) blockers potentially useful for the treatment of heart failure, arrhythmia, primary hyperaldosteronism and hypertension.
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have identified new calcitonin receptor (CALCR; CT-R) and amylin receptor dual agonists potentially useful for the treatment of metabolic dysfunction-associated steatohepatitis (MASH; NASH), overweight, dyslipidemia, cognitive and cardiovascular disorders.
Merck KGaA has entered into a strategic research-stage collaboration with Saturnus Bio, a biotech founded by Versant Ventures, to establish a foundational portfolio in the field of rare genetic cardiomyopathies.
Scribe Therapeutics Inc. has been awarded more than $25 million by California Institute for Regenerative Medicine (CIRM) across two preclinical programs for CRISPR-based gene editing therapies targeting cardiovascular and metabolic disease.
Chengdu Shibeikang Biological Medicine Technology Co. Ltd. has patented new platelet adhesion inhibitors reported to be useful for the treatment of cardiovascular and cerebrovascular disorders.
Thryv Therapeutics Inc. has divulged new crystalline forms of serum/glucocorticoid-regulated kinase 1 (SGK1) inhibitors and maleic acid potentially useful for the treatment of atrial fibrillation, heart failure and inflammatory disorders.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized relaxin family peptide receptor 1 (RXFP1) receptor agonists reported to be potentially useful for the treatment of heart failure.
Leto Laboratories Co. Ltd. has identified macro cyclic peptides acting as calcitonin receptor (CALCR; CT-R) and amylin dual receptor agonists reported to be potentially useful for the treatment of atherosclerosis, type 1 diabetes, dyspepsia, myocardial infarction, obesity and more.
Bristol Myers Squibb Co. (BMS) has disclosed new 1H-benzo[d]imidazole derivatives acting as calcium/calmodulin-dependent protein kinase type II (CAMK2) inhibitors potentially useful for the treatment of anxiety disorders, asthma, cardiomyopathy, diabetes, fibrosis, heart failure, hypertension and allergy, among others.
Protuoso Biosciences has announced the close of an oversubscribed $9.5 million seed financing round, the proceeds of which will be used to advance its multifunctional protein engineering platform and broad pipeline across cardiometabolic, oncology and autoimmune diseases.
RSS
